{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:10:52Z","timestamp":1790143852195,"version":"4.0.1"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-022-01864-z","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T03:04:37Z","timestamp":1667012677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer"],"prefix":"10.1007","volume":"40","author":[{"given":"Adarsh","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshwardhan","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Thareja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4284-2826","authenticated-orcid":false,"given":"Pradeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"key":"1864_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin. 2018;68:394\u2013424.","journal-title":"Ca-Cancer J Clin."},{"key":"1864_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","volume":"66","author":"M Arnold","year":"2017","unstructured":"Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683\u201391.","journal-title":"Gut"},{"key":"1864_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524\u201348.","journal-title":"JAMA Oncol"},{"key":"1864_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Ca-Cancer J Clin. 2020;70:7\u201330.","journal-title":"Ca-Cancer J Clin."},{"key":"1864_CR5","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1136\/gutjnl-2019-319511","volume":"68","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Torre LA, Soerjomataram I, Hayes RB, Bray F, Weber TK, et al. Global patterns and trends in colorectal cancer incidence in young adults. Gut. 2019;68:2179\u201385.","journal-title":"Gut"},{"key":"1864_CR6","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/ijc.30527","volume":"140","author":"A Buron Pust","year":"2017","unstructured":"Buron Pust A, Alison R, Blanks R, Pirie K, Gaitskell K, Barnes I, et al. Heterogeneity of colorectal cancer risk by tumour characteristics: Large prospective study of UK women. Int J Cancer. 2017;140:1082\u201390.","journal-title":"Int J Cancer"},{"key":"1864_CR7","unstructured":"American Cancer Society. 2020 Colorectal cancer facts & figures 2020\u20132022. Published online. 48."},{"key":"1864_CR8","doi-asserted-by":"publisher","first-page":"643020","DOI":"10.1155\/2015\/643020","volume":"2015","author":"R Dolatkhah","year":"2015","unstructured":"Dolatkhah R, Somi MH, Bonyadi MJ, Asvadi Kermani I, Farassati F, Dastgiri S. Colorectal cancer in Iran: molecular epidemiology and screening strategies. J Cancer Epidemiol. 2015;2015:643020.","journal-title":"J Cancer Epidemiol"},{"key":"1864_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-2-1","volume":"2","author":"S Narayan","year":"2003","unstructured":"Narayan S, Roy D. Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer. 2003;2:1\u201315.","journal-title":"Mol Cancer"},{"key":"1864_CR10","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1053\/j.gastro.2016.02.062","volume":"150","author":"SI Grivennikov","year":"2016","unstructured":"Grivennikov SI, Cominelli F. Colitis-associated and sporadic colon cancers: different diseases, different mutations? Gastroenterology. 2016;150:808\u201310.","journal-title":"Gastroenterology"},{"key":"1864_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-015-0066-y","volume":"35","author":"H Yamagishi","year":"2016","unstructured":"Yamagishi H, Kuroda H, Imai Y, Hiraishi H. Molecular pathogenesis of sporadic colorectal cancers. Chin J Cancer. 2016;35:1\u20138.","journal-title":"Chin J Cancer"},{"key":"1864_CR12","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.3748\/wjg.v23.i28.5086","volume":"23","author":"IA Issa","year":"2017","unstructured":"Issa IA, Noureddine M. Colorectal cancer screening: an updated review of the available options. World J Gastroenterol. 2017;23:5086.","journal-title":"World J Gastroenterol"},{"key":"1864_CR13","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","volume":"383","author":"H Brenner","year":"2014","unstructured":"Brenner H, Kloor M, Pox C. Colorectal cancer. Lancet. 2014;383:1490\u2013502.","journal-title":"Lancet"},{"key":"1864_CR14","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/carcin\/bgy186","volume":"40","author":"A Sakatani","year":"2019","unstructured":"Sakatani A, Sonohara F, Goel A. Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. Carcinogenesis. 2019;40:422\u201331.","journal-title":"Carcinogenesis"},{"key":"1864_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1503\/cmaj.045113","volume":"174","author":"J Brierley","year":"2006","unstructured":"Brierley J. The evolving TNM cancer staging system: an essential Component of cancer care. CMAJ. 2006;174:155\u20136.","journal-title":"CMAJ"},{"key":"1864_CR16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.critrevonc.2012.09.014","volume":"86","author":"J Mishra","year":"2013","unstructured":"Mishra J, Drummond J, Quazi SH, Karanki SS, Shaw J, Chen B, et al. Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. Crit Rev Oncol Hematol. 2013;86:232\u201350.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1864_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1055\/s-0035-1564430","volume":"28","author":"A Varghese","year":"2015","unstructured":"Varghese A. Chemotherapy for stage II colon cancer. Clin Colon Rectal Surg. 2015;28:256\u201361.","journal-title":"Clin Colon Rectal Surg"},{"key":"1864_CR18","doi-asserted-by":"publisher","first-page":"a021709","DOI":"10.1101\/cshperspect.a021709","volume":"7","author":"RD Hawkins","year":"2015","unstructured":"Hawkins RD, Byrne JH. Associative learning in invertebrates. Cold Spring Harb Perspect Biol. 2015;7:a021709.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1864_CR19","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrc2657","volume":"9","author":"T Abbas","year":"2009","unstructured":"Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400\u201314.","journal-title":"Nat Rev Cancer"},{"key":"1864_CR20","first-page":"145","volume":"9","author":"JD Amaral","year":"2010","unstructured":"Amaral JD, Xavier JM, Steer CJ, Rodrigues CM. The role of p53 in apoptosis. Discov Med. 2010;9:145\u201352.","journal-title":"Discov Med"},{"key":"1864_CR21","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/nrc2254","volume":"7","author":"R Mathew","year":"2007","unstructured":"Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer. 2007;7:961\u20137.","journal-title":"Nat Rev Cancer"},{"key":"1864_CR22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.acthis.2011.01.002","volume":"113","author":"Y Jin-Song","year":"2011","unstructured":"Jin-Song Y, Zhao-Xia W, Cheng-Yu L, Xiao-Di L, Ming S, Yuan-Yuan G, et al. Prognostic significance of Bcl-xL gene expression in human colorectal cancer. Acta Histochem. 2011;113:810\u20134.","journal-title":"Acta Histochem"},{"key":"1864_CR23","doi-asserted-by":"publisher","first-page":"e2342","DOI":"10.1038\/cddis.2016.233","volume":"7","author":"A-L Scherr","year":"2016","unstructured":"Scherr A-L, Gdynia G, Salou M, Radhakrishnan P, Duglova K, Heller A, et al. Bcl-xL is an oncogenic driver in colorectal cancer. Cell Death Dis. 2016;7:e2342.","journal-title":"Cell Death Dis"},{"key":"1864_CR24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/ijc.10146","volume":"98","author":"S Violette","year":"2002","unstructured":"Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, et al. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-XL in addition to Bax and p53 status. Int J Cancer. 2002;98:498\u2013504.","journal-title":"Int J Cancer"},{"key":"1864_CR25","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/cdd.2014.170","volume":"22","author":"D Wu","year":"2015","unstructured":"Wu D, Huang C, Chang S, Chen T, Lee H. Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer. Cell Death Differ. 2015;22:779\u201389.","journal-title":"Cell Death Differ"},{"key":"1864_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nsmb.3216","volume":"23","author":"KP Locher","year":"2016","unstructured":"Locher KP. Mechanistic diversity in ATP-binding cassette (ABC) transporters. Nat Struct Mol Biol. 2016;23:487\u201393.","journal-title":"Nat Struct Mol Biol"},{"key":"1864_CR27","first-page":"2401","volume":"6","author":"E Hinoshita","year":"2000","unstructured":"Hinoshita E, Uchiumi T, Taguchi K-i, Kinukawa N, Tsuneyoshi M, Maehara Y, et al. Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. Clin Cancer Res. 2000;6:2401\u20137.","journal-title":"Clin Cancer Res"},{"key":"1864_CR28","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/0959-8049(95)00278-Q","volume":"31","author":"S Linn","year":"1995","unstructured":"Linn S, Giaccone G. MDR1\/P-glycoprotein expression in colorectal cancer. Eur J Cancer. 1995;31:1291\u20134.","journal-title":"Eur J Cancer"},{"key":"1864_CR29","doi-asserted-by":"publisher","first-page":"11166","DOI":"10.1074\/jbc.RA118.003187","volume":"293","author":"Q Guo","year":"2018","unstructured":"Guo Q, Grimmig T, Gonzalez G, Giobbie-Hurder A, Berg G, Carr N, et al. ATP-binding cassette member B5 (ABCB5) promotes tumor cell invasiveness in human colorectal cancer. J Biol Chem. 2018;293:11166\u201378.","journal-title":"J Biol Chem"},{"key":"1864_CR30","doi-asserted-by":"publisher","first-page":"9499","DOI":"10.1007\/s13277-015-3636-3","volume":"36","author":"Z Wang","year":"2015","unstructured":"Wang Z, Zhang L, Ni Z, Sun J, Gao H, Cheng Z, et al. Resveratrol induces AMPK-dependent MDR1 inhibition in colorectal cancer HCT116\/L-OHP cells by preventing activation of NF-\u03baB signaling and suppressing cAMP-responsive element transcriptional activity. Tumour Biol. 2015;36:9499\u2013510.","journal-title":"Tumour Biol"},{"key":"1864_CR31","doi-asserted-by":"publisher","first-page":"8747","DOI":"10.3892\/mmr.2017.7721","volume":"16","author":"J Wang","year":"2017","unstructured":"Wang J, Wang W, Cai H, Du B, Zhang L, Ma W, et al. MACC1 facilitates chemoresistance and cancer stem celllike properties of colon cancer cells through the PI3K\/AKT signaling pathway. Mol Med Rep. 2017;16:8747\u201354.","journal-title":"Mol Med Rep"},{"key":"1864_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.dnarep.2014.07.001","volume":"22","author":"B Yousefi","year":"2014","unstructured":"Yousefi B, Samadi N, Ahmadi Y. Akt and p53R2, partners that dictate the progression and invasiveness of cancer. DNA Repair. 2014;22:24\u20139.","journal-title":"DNA Repair"},{"key":"1864_CR33","doi-asserted-by":"publisher","first-page":"ra121","DOI":"10.1126\/scisignal.aaa1877","volume":"7","author":"CA Martz","year":"2014","unstructured":"Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal. 2014;7:ra121.","journal-title":"Sci Signal."},{"key":"1864_CR34","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.2174\/13816128112092464","volume":"18","author":"J Cui","year":"2012","unstructured":"Cui J, Jiang W, Wang S, Wang L, Xie K. Role of Wnt\/\u03b2-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des. 2012;18:2464\u201371.","journal-title":"Curr Pharm Des"},{"key":"1864_CR35","first-page":"120","volume":"3","author":"P Egodwin","year":"2013","unstructured":"Egodwin P, Ebaird A, Eheavey S, Ebarr M, O\u2019Byrne K, Gately K. Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol. 2013;3:120.","journal-title":"Front Oncol"},{"key":"1864_CR36","first-page":"2041","volume":"30","author":"N Chikazawa","year":"2010","unstructured":"Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H, et al. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res. 2010;30:2041\u20138.","journal-title":"Anticancer Res"},{"key":"1864_CR37","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/cas.13097","volume":"107","author":"M Kobayashi","year":"2016","unstructured":"Kobayashi M, Funayama R, Ohnuma S, Unno M, Nakayama K. Wnt-\u03b2-catenin signaling regulates ABCC 3 (MRP 3) transporter expression in colorectal cancer. Cancer Sci. 2016;107:1776\u201384.","journal-title":"Cancer Sci"},{"key":"1864_CR38","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1002\/jcb.26783","volume":"119","author":"E Kukcinaviciute","year":"2018","unstructured":"Kukcinaviciute E, Jonusiene V, Sasnauskiene A, Dabkeviciene D, Eidenaite E, Laurinavicius A. Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116. J Cell Biochem. 2018;119:5913\u201320.","journal-title":"J Cell Biochem"},{"key":"1864_CR39","doi-asserted-by":"publisher","first-page":"14585","DOI":"10.1002\/jcb.28720","volume":"120","author":"R Xu","year":"2019","unstructured":"Xu R, Yin J, Zhang Y, Zhang S. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway. J Cell Biochem. 2019;120:14585\u201393.","journal-title":"J Cell Biochem"},{"key":"1864_CR40","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.2147\/OTT.S108929","volume":"9","author":"K Yang","year":"2016","unstructured":"Yang K, Gao K, Hu G, Wen Y, Lin C, Li X. CTGF enhances resistance to 5-FU-mediating cell apoptosis through FAK\/MEK\/ERK signal pathway in colorectal cancer. Onco Targets Ther. 2016;9:7285.","journal-title":"Onco Targets Ther"},{"key":"1864_CR41","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20160447","author":"J Xu","year":"2017","unstructured":"Xu J, Zhang S, Wang R, Wu X, Zeng L, Fu Z. Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K\/AKT signaling pathway. 2017. Biosci Rep. https:\/\/doi.org\/10.1042\/BSR20160447."},{"key":"1864_CR42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1200\/JCO.2004.05.064","volume":"22","author":"S Popat","year":"2004","unstructured":"Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004;22:529\u201336.","journal-title":"J Clin Oncol"},{"key":"1864_CR43","first-page":"4116","volume":"9","author":"M Kornmann","year":"2003","unstructured":"Kornmann M, Schwabe W, Sander S, Kron M, Str\u00e4ter J, Polat S, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res. 2003;9:4116\u201324.","journal-title":"Clin Cancer Res"},{"key":"1864_CR44","first-page":"1322","volume":"6","author":"D Salonga","year":"2000","unstructured":"Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res. 2000;6:1322\u20137.","journal-title":"Clin Cancer Res"},{"key":"1864_CR45","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.surg.2005.10.012","volume":"139","author":"R Douard","year":"2006","unstructured":"Douard R, Moutereau S, Pernet P, Chimingqi M, Allory Y, Manivet P, et al. Sonic Hedgehog\u2013dependent proliferation in a series of patients with colorectal cancer. Surgery. 2006;139:665\u201370.","journal-title":"Surgery"},{"key":"1864_CR46","doi-asserted-by":"publisher","first-page":"8574","DOI":"10.18632\/oncotarget.14351","volume":"8","author":"T Xie","year":"2017","unstructured":"Xie T, Geng J, Wang Y, Wang L, Huang M, Chen J, et al. FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. Oncotarget. 2017;8:8574.","journal-title":"Oncotarget"},{"key":"1864_CR47","doi-asserted-by":"publisher","first-page":"32622","DOI":"10.18632\/oncotarget.5327","volume":"6","author":"J-Y Ahn","year":"2015","unstructured":"Ahn J-Y, Lee J-S, Min H-Y, Lee H-Y. Acquired resistance to 5-fluorouracil via HSP90\/Src-mediated increase in thymidylate synthase expression in colon cancer. Oncotarget. 2015;6:32622.","journal-title":"Oncotarget"},{"key":"1864_CR48","doi-asserted-by":"publisher","first-page":"118255","DOI":"10.1016\/j.lfs.2020.118255","volume":"259","author":"M Vaghari-Tabari","year":"2020","unstructured":"Vaghari-Tabari M, Majidinia M, Moein S, Qujeq D, Asemi Z, Alemi F, et al. MicroRNAs and colorectal cancer chemoresistance: new solution for old problem. Life Sci. 2020;259:118255.","journal-title":"Life Sci"},{"key":"1864_CR49","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/35055027","volume":"3","author":"P Liston","year":"2001","unstructured":"Liston P, Fong WG, Kelly NL, Toji S, Miyazaki T, Conte D, et al. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nat Cell Biol. 2001;3:128\u201333.","journal-title":"Nat Cell Biol"},{"key":"1864_CR50","first-page":"2117","volume":"54","author":"JR Moon","year":"2019","unstructured":"Moon JR, Oh SJ, Lee CK, Chi SG, Kim HJ. TGF-\u03b21 protects colon tumor cells from apoptosis through XAF1 suppression. Int J Oncol. 2019;54:2117\u201326.","journal-title":"Int J Oncol"},{"key":"1864_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1143-x","volume":"38","author":"Q Liang","year":"2019","unstructured":"Liang Q, Tang C, Tang M, Zhang Q, Gao Y, Ge Z. TRIM47 is up-regulated in colorectal cancer, promoting ubiquitination and degradation of SMAD4. J Exp Clin Cancer Res. 2019;38:1\u201314.","journal-title":"J Exp Clin Cancer Res"},{"key":"1864_CR52","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.biocel.2016.07.024","volume":"78","author":"M Sakowicz-Burkiewicz","year":"2016","unstructured":"Sakowicz-Burkiewicz M, Przybyla T, Wesserling M, Bielarczyk H, Maciejewska I, Pawelczyk T. Suppression of TWIST1 enhances the sensitivity of colon cancer cells to 5-fluorouracil. Int J Biochem Cell Biol. 2016;78:268\u201378.","journal-title":"Int J Biochem Cell Biol"},{"key":"1864_CR53","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.21873\/anticanres.13672","volume":"39","author":"CW Yun","year":"2019","unstructured":"Yun CW, Lee JH, Lee SH. Hypoxia-induced PGC-1\u03b1 regulates mitochondrial function and tumorigenesis of colorectal cancer cells. Anticancer Res. 2019;39:4865\u201376.","journal-title":"Anticancer Res"},{"key":"1864_CR54","first-page":"2102","volume":"53","author":"Z Wang","year":"2018","unstructured":"Wang Z, Zhao X, Wang W, Liu Y, Li Y, Gao J, et al. ZBTB7 evokes 5-fluorouracil resistance in colorectal cancer through the NF\u03baB signaling pathway. Int J Oncol. 2018;53:2102\u201310.","journal-title":"Int J Oncol"},{"key":"1864_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0701-2","volume":"7","author":"D Wang","year":"2019","unstructured":"Wang D, Yang L, Yu W, Wu Q, Lian J, Li F, et al. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1\/CEBPB\/NF-\u03baB signaling. J Immunother Cancer. 2019;7:1\u201315.","journal-title":"J Immunother Cancer"},{"key":"1864_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13578-017-0145-7","volume":"7","author":"L Zhang","year":"2017","unstructured":"Zhang L, Song R, Gu D, Zhang X, Yu B, Liu B, et al. The role of GLI1 for 5-Fu resistance in colorectal cancer. Cell Biosci. 2017;7:1\u20139.","journal-title":"Cell Biosci"},{"key":"1864_CR57","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3727\/096504016X14772331883976","volume":"25","author":"F Zhang","year":"2017","unstructured":"Zhang F, Sun H, Zhang S, Yang X, Zhang G, Su T. Overexpression of PER3 inhibits self-renewal capability and chemoresistance of colorectal cancer stem-like cells via inhibition of notch and \u03b2-catenin signaling. Oncol Res. 2017;25:709.","journal-title":"Oncol Res"},{"key":"1864_CR58","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.7150\/jca.19142","volume":"8","author":"L Sun","year":"2017","unstructured":"Sun L, Ke J, He Z, Chen Z, Huang Q, Ai W, et al. HES1 promotes colorectal cancer cell resistance to 5-Fu by inducing of EMT and ABC transporter proteins. J Cancer. 2017;8:2802.","journal-title":"J Cancer"},{"key":"1864_CR59","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/mc.22883","volume":"57","author":"R Song","year":"2018","unstructured":"Song R, Gu D, Zhang L, Zhang X, Yu B, Liu B, et al. Functional significance of Hippo\/YAP signaling for drug resistance in colorectal cancer. Mol Carcinog. 2018;57:1608\u201315.","journal-title":"Mol Carcinog"},{"key":"1864_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0128-8","volume":"50","author":"L He","year":"2018","unstructured":"He L, Zhu H, Zhou S, Wu T, Wu H, Yang H, et al. Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells. Exp Mol Med. 2018;50:1\u201312.","journal-title":"Exp Mol Med"},{"key":"1864_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0848-3","volume":"17","author":"SB Uppada","year":"2018","unstructured":"Uppada SB, Gowrikumar S, Ahmad R, Kumar B, Szeglin B, Chen X, et al. MASTL induces colon cancer progression and chemoresistance by promoting Wnt\/\u03b2-catenin signaling. Mol Cancer. 2018;17:1\u201315.","journal-title":"Mol Cancer"},{"key":"1864_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep04694","volume":"4","author":"X Sui","year":"2014","unstructured":"Sui X, Kong N, Wang X, Fang Y, Hu X, Xu Y, et al. RETRACTED ARTICLE: JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy. Sci Rep. 2014;4:1\u20138.","journal-title":"Sci Rep"},{"key":"1864_CR63","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/onc.2011.321","volume":"31","author":"M De la Cruz-Morcillo","year":"2012","unstructured":"De la Cruz-Morcillo M, Valero M, Callejas-Valera J, Arias-Gonzalez L, Melgar-Rojas P, Gal\u00e1n-Moya E, et al. P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance. Oncogene. 2012;31:1073\u201385.","journal-title":"Oncogene"},{"key":"1864_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-08902-x","volume":"10","author":"J Ou","year":"2019","unstructured":"Ou J, Peng Y, Yang W, Zhang Y, Hao J, Li F, et al. ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield. Nat Commun. 2019;10:1\u201314.","journal-title":"Nat Commun"},{"key":"1864_CR65","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s12094-018-1840-5","volume":"20","author":"H Cui","year":"2018","unstructured":"Cui H, Yang S, Jiang Y, Li C, Zhao Y, Shi Y, et al. The glycosyltransferase ST6Gal-I is enriched in cancer stem-like cells in colorectal carcinoma and contributes to their chemo-resistance. Clin Transl Oncol. 2018;20:1175\u201384.","journal-title":"Clin Transl Oncol"},{"key":"1864_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-017-0483-x","volume":"17","author":"MF Rubio","year":"2017","unstructured":"Rubio MF, Lira MC, Rosa FD, Sambresqui AD, Salazar G\u00fcemes MC, Costas MA. RAC3 influences the chemoresistance of colon cancer cells through autophagy and apoptosis inhibition. Cancer Cell Int. 2017;17:1\u201317.","journal-title":"Cancer Cell Int"},{"key":"1864_CR67","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3816\/CCC.2009.n.007","volume":"8","author":"K Derwinger","year":"2009","unstructured":"Derwinger K, Wettergren Y, Odin E, Carlsson G, Gustavsson B. A study of the MTHFR gene polymorphism C677T in colorectal cancer. Clin Colorectal Cancer. 2009;8:43\u20138.","journal-title":"Clin Colorectal Cancer"},{"key":"1864_CR68","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1200\/JCO.1997.15.10.3223","volume":"15","author":"CG Leichman","year":"1997","unstructured":"Leichman CG, Lenz H-J, Leichman L, Danenberg K, Baranda J, Groshen S, et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. 1997;15:3223\u20139.","journal-title":"J Clin Oncol"},{"key":"1864_CR69","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/cncr.30967","volume":"124","author":"NJ Meropol","year":"2018","unstructured":"Meropol NJ, Feng Y, Grem JL, Mulcahy MF, Catalano PJ, Kauh JS, et al. Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: a trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer. 2018;124:688\u201397.","journal-title":"Cancer"},{"key":"1864_CR70","doi-asserted-by":"publisher","first-page":"364","DOI":"10.4161\/cbt.2.4.424","volume":"2","author":"BJ Dolnick","year":"2003","unstructured":"Dolnick BJ, Angelino NJ, Dolnick R, Sufrin JR. A novel function for the rTS gene. Cancer Biol Ther. 2003;2:364\u20139.","journal-title":"Cancer Biol Ther"},{"key":"1864_CR71","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/gutjnl-2013-306571","volume":"64","author":"D Rosmarin","year":"2015","unstructured":"Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut. 2015;64:111\u201320.","journal-title":"Gut"},{"key":"1864_CR72","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/mc.20470","volume":"48","author":"G Liu","year":"2009","unstructured":"Liu G, Hu X, Varani J, Chakrabarty S. Calcium and calcium sensing receptor modulates the expression of thymidylate synthase, NAD (P) H: quinone oxidoreductase 1 and survivin in human colon carcinoma cells: promotion of cytotoxic response to mitomycin C and fluorouracil. Mol Carcinog. 2009;48:202\u201311.","journal-title":"Mol Carcinog"},{"key":"1864_CR73","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1002\/ijc.28270","volume":"133","author":"N Singh","year":"2013","unstructured":"Singh N, Chakrabarty S. Induction of CaSR expression circumvents the molecular features of malignant CaSR null colon cancer cells. Int J Cancer. 2013;133:2307\u201314.","journal-title":"Int J Cancer"},{"key":"1864_CR74","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/ijc.24762","volume":"126","author":"G Liu","year":"2010","unstructured":"Liu G, Hu X, Chakrabarty S. Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU. Int J Cancer. 2010;126:631\u20139.","journal-title":"Int J Cancer"},{"key":"1864_CR75","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jsbmb.2019.03.017","volume":"190","author":"M Milczarek","year":"2019","unstructured":"Milczarek M, Rossowska J, Klopotowska D, Stachowicz M, Kutner A, Wietrzyk J. Tacalcitol increases the sensitivity of colorectal cancer cells to 5-fluorouracil by downregulating the thymidylate synthase. J Steroid Biochem Mol. 2019;190:139\u201351.","journal-title":"J Steroid Biochem Mol"},{"key":"1864_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-38017-0","volume":"9","author":"V Varghese","year":"2019","unstructured":"Varghese V, Magnani L, Harada-Shoji N, Mauri F, Szydlo RM, Yao S, et al. FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression. Sci Rep. 2019;9:1\u201316.","journal-title":"Sci Rep"},{"key":"1864_CR77","first-page":"172","volume":"10","author":"T Ma","year":"2004","unstructured":"Ma T, Zhu Z-G, Ji Y-B, Zhang Y, Yu Y-Y, Liu B-Y, et al. Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2\u2019-deoxyuridine. World J Gastroenterol. 2004;10:172.","journal-title":"World J Gastroenterol"},{"key":"1864_CR78","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.ejca.2006.09.026","volume":"43","author":"T Kobunai","year":"2007","unstructured":"Kobunai T, Ooyama A, Sasaki S, Wierzba K, Takechi T, Fukushima M, et al. Changes to the dihydropyrimidine dehydrogenase gene copy number influence the susceptibility of cancers to 5-FU-based drugs: data mining of the NCI-DTP data sets and validation with human tumour xenografts. Eur J Cancer. 2007;43:791\u20138.","journal-title":"Eur J Cancer"},{"key":"1864_CR79","first-page":"729","volume":"19","author":"H Yamada","year":"2008","unstructured":"Yamada H, Iinuma H, Watanabe T. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes\u2019 stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy. Oncol Rep. 2008;19:729\u201335.","journal-title":"Oncol Rep"},{"key":"1864_CR80","first-page":"1343","volume":"7","author":"H Elsaleh","year":"2001","unstructured":"Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D, et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res. 2001;7:1343\u20139.","journal-title":"Clin Cancer Res"},{"key":"1864_CR81","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1172\/JCI6863","volume":"104","author":"F Bunz","year":"1999","unstructured":"Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Investig. 1999;104:263\u20139.","journal-title":"J Clin Investig"},{"key":"1864_CR82","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/ijc.1637","volume":"97","author":"JT Liang","year":"2002","unstructured":"Liang JT, Huang KC, Cheng YM, Hsu HC, Cheng AL, Hsu CH, et al. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer. 2002;97:451\u20137.","journal-title":"Int J Cancer"},{"key":"1864_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-09859-x","volume":"7","author":"P Gokare","year":"2017","unstructured":"Gokare P, Finnberg NK, Abbosh PH, Dai J, Murphy ME, El-Deiry WS. P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting. Sci Rep. 2017;7:1\u201312.","journal-title":"Sci Rep"},{"key":"1864_CR84","first-page":"1149","volume":"58","author":"DJ Ahnen","year":"1998","unstructured":"Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest oncology group study. Cancer Res. 1998;58:1149\u201358.","journal-title":"Cancer Res"},{"key":"1864_CR85","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00280-012-2054-0","volume":"71","author":"LC Phua","year":"2013","unstructured":"Phua LC, Mal M, Koh PK, Cheah PY, Chan ECY, Ho HK. Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy. Cancer Chemother Pharmacol. 2013;71:817\u201323.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1864_CR86","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1016\/j.ejca.2010.07.011","volume":"46","author":"RG Watson","year":"2010","unstructured":"Watson RG, Muhale F, Thorne LB, Yu J, O\u2019Neil BH, Hoskins JM, et al. Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. Eur J Cancer. 2010;46:3358\u201364.","journal-title":"Eur J Cancer"},{"key":"1864_CR87","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S0959-8049(01)00174-5","volume":"37","author":"M Fukushima","year":"2001","unstructured":"Fukushima M, Fujioka A, Uchida J, Nakagawa F, Takechi T. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer. 2001;37:1681\u20137.","journal-title":"Eur J Cancer"},{"key":"1864_CR88","first-page":"277","volume":"17","author":"Y Murakami","year":"2000","unstructured":"Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N, Fukushima M. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol. 2000;17:277\u2013360.","journal-title":"Int J Oncol"},{"key":"1864_CR89","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/annonc\/mdm599","volume":"19","author":"R Soong","year":"2008","unstructured":"Soong R, Shah N, Salto-Tellez M, Tai B, Soo R, Han H, et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol. 2008;19:915\u20139.","journal-title":"Ann Oncol"},{"key":"1864_CR90","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/path.1663","volume":"204","author":"C Jakob","year":"2004","unstructured":"Jakob C, Aust DE, Meyer W, Baretton GB, Schwabe W, H\u00e4usler P, et al. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. J Pathol. 2004;204:562\u20138.","journal-title":"J Pathol"},{"key":"1864_CR91","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/15384047.2017.1416936","volume":"19","author":"S Ibrahim","year":"2018","unstructured":"Ibrahim S, Li G, Hu F, Hou Z, Chen Q, Li G, et al. PIK3R3 promotes chemotherapeutic sensitivity of colorectal cancer through PIK3R3\/NF-kB\/TP pathway. Cancer Biol Ther. 2018;19:222\u20139.","journal-title":"Cancer Biol Ther"},{"key":"1864_CR92","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/jcp.2008.060004","volume":"62","author":"A Kawahara","year":"2009","unstructured":"Kawahara A, Akagi Y, Hattori S, Mizobe T, Shirouzu K, Ono M, et al. Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer. J Clin Pathol. 2009;62:364\u20139.","journal-title":"J Clin Pathol"},{"key":"1864_CR93","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3892\/or.2014.3299","volume":"32","author":"T Ochiai","year":"2014","unstructured":"Ochiai T, Umeki M, Miyake H, Iida T, Okumura M, Ohno K, et al. Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer. Oncol Rep. 2014;32:887\u201392.","journal-title":"Oncol Rep"},{"key":"1864_CR94","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41417-018-0030-5","volume":"25","author":"E Durinikova","year":"2018","unstructured":"Durinikova E, Plava J, Tyciakova S, Skvara P, Vojs Stanova A, Kozovska Z, et al. Cytotoxic response of 5-fluorouracil-resistant cells to gene-and cell-directed enzyme\/prodrug treatment. Cancer Gene Ther. 2018;25:285\u201399.","journal-title":"Cancer Gene Ther"},{"key":"1864_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-13-149","volume":"13","author":"M Ishiguro","year":"2013","unstructured":"Ishiguro M, Kotake K, Nishimura G, Tomita N, Ichikawa W, Takahashi K, et al. Study protocol of the B-CAST study: a multicenter, prospective cohort study investigating the tumor biomarkers in adjuvant chemotherapy for stage III colon cancer. BMC Cancer. 2013;13:1\u20139.","journal-title":"BMC Cancer"},{"key":"1864_CR96","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3892\/or.2012.2177","volume":"29","author":"T Mori","year":"2013","unstructured":"Mori T, Ohue M, Takii Y, Hashizume T, Kato T, Kotake K, et al. Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study). Oncol Rep. 2013;29:437\u201344.","journal-title":"Oncol Rep"},{"key":"1864_CR97","first-page":"3493","volume":"60","author":"RD Ladner","year":"2000","unstructured":"Ladner RD, Lynch FJ, Groshen S, Xiong YP, Sherrod A, Caradonna SJ, et al. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. Cancer Res. 2000;60:3493\u2013503.","journal-title":"Cancer Res"},{"key":"1864_CR98","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/oxfordjournals.annonc.a059353","volume":"6","author":"A Jackman","year":"1995","unstructured":"Jackman A, Calvert A. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol. 1995;6:871\u201381.","journal-title":"Ann Oncol"},{"key":"1864_CR99","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S0959-8049(03)00204-1","volume":"39","author":"H Backus","year":"2003","unstructured":"Backus H, Wouters D, Ferreira C, Van Houten V, Brakenhoff R, Pinedo H, et al. Thymidylate synthase inhibition triggers apoptosis via caspases-8 and-9 in both wild-type and mutant p53 colon cancer cell lines. Eur J Cancer. 2003;39:1310\u20137.","journal-title":"Eur J Cancer"},{"key":"1864_CR100","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.canlet.2020.05.023","volume":"488","author":"SR Satapathy","year":"2020","unstructured":"Satapathy SR, Sj\u00f6lander A. Cysteinyl leukotriene receptor 1 promotes 5-fluorouracil resistance and resistance-derived stemness in colon cancer cells. Cancer Lett. 2020;488:50\u201362.","journal-title":"Cancer Lett"},{"key":"1864_CR101","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.3748\/wjg.v19.i42.7374","volume":"19","author":"D Das","year":"2013","unstructured":"Das D, Preet R, Mohapatra P, Satapathy SR, Kundu CN. 1, 3-Bis (2-chloroethyl)-1-nitrosourea enhances the inhibitory effect of resveratrol on 5-fluorouracil sensitive\/resistant colon cancer cells. World J Gastroenterol. 2013;19:7374.","journal-title":"World J Gastroenterol"},{"key":"1864_CR102","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.1997.15.6.2432","volume":"15","author":"A Zaniboni","year":"1997","unstructured":"Zaniboni A. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. J Clin Oncol. 1997;15:2432\u201341.","journal-title":"J Clin Oncol"},{"key":"1864_CR103","first-page":"79","volume":"3","author":"BR Hirsch","year":"2011","unstructured":"Hirsch BR, Zafar SY. Capecitabine in the management of colorectal cancer. Cancer Manag Res. 2011;3:79.","journal-title":"Cancer Manag Res."},{"key":"1864_CR104","first-page":"81","volume":"23","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Salo-Ahen O, Guaitoli G, Ferrari S, Venturelli A, Franchini S, et al. Design and characterization of a mutation outside the active site of human thymidylate synthase that affects ligand binding. Protein eng. Des; & Sel. 2010;23:81\u20139.","journal-title":"Des; & Sel."},{"key":"1864_CR105","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/cmdc.200700215","volume":"3","author":"S Ferrari","year":"2008","unstructured":"Ferrari S, Losasso V, Costi MP. Sequence-based identification of specific drug target regions in the thymidylate synthase enzyme family. ChemMedChem. 2008;3:392\u2013401.","journal-title":"ChemMedChem"},{"key":"1864_CR106","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.mam.2016.11.005","volume":"53","author":"J Chon","year":"2017","unstructured":"Chon J, Stover PJ, Field MS. Targeting nuclear thymidylate biosynthesis. Mol Aspects Med. 2017;53:48\u201356.","journal-title":"Mol Aspects Med"},{"key":"1864_CR107","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cllc.2017.06.013","volume":"19","author":"JC-H Yang","year":"2018","unstructured":"Yang JC-H, Mok T, Han B, Orlando M, Puri T, Park K. A review of regimens combining pemetrexed with an epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of advanced nonsquamous non\u2013small-cell lung cancer. Clin lung cancer. 2018;19:27\u201334.","journal-title":"Clin lung cancer"},{"key":"1864_CR108","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1016\/j.bmcl.2014.07.049","volume":"24","author":"VP Kumar","year":"2014","unstructured":"Kumar VP, Cisneros JA, Frey KM, Castellanos-Gonzalez A, Wang Y, Gangjee A, et al. Structural studies provide clues for analog design of specific inhibitors of Cryptosporidium hominis thymidylate synthase\u2013dihydrofolate reductase. Bioorg Med Chem Lett. 2014;24:4158\u201361.","journal-title":"Bioorg Med Chem Lett"},{"key":"1864_CR109","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/bjc.2011.129","volume":"104","author":"K Takezawa","year":"2011","unstructured":"Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer. 2011;104:1594\u2013601.","journal-title":"Br J Cancer"},{"key":"1864_CR110","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/bjc.1995.179","volume":"71","author":"S Freemantle","year":"1995","unstructured":"Freemantle S, Jackman A, Kelland L, Calvert A, Lunec J. Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694. Br J Cancer. 1995;71:925\u201330.","journal-title":"Br J Cancer"},{"key":"1864_CR111","first-page":"5505","volume":"61","author":"W Wang","year":"2001","unstructured":"Wang W, Marsh S, Cassidy J, McLeod HL. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res. 2001;61:5505\u201310.","journal-title":"Cancer Res"},{"key":"1864_CR112","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1158\/1078-0432.CCR-10-2873","volume":"17","author":"PA Zucali","year":"2011","unstructured":"Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed\/carboplatin. Clin Cancer Res. 2011;17:2581\u201390.","journal-title":"Clin Cancer Res"},{"key":"1864_CR113","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1158\/1541-7786.MCR-08-0519","volume":"7","author":"DR McNeill","year":"2009","unstructured":"McNeill DR, Lam W, DeWeese TL, Cheng Y-C, Wilson DM. Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol Cancer Res. 2009;7:897\u2013906.","journal-title":"Mol Cancer Res"},{"key":"1864_CR114","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1038\/cddis.2011.135","volume":"3","author":"A Bulgar","year":"2012","unstructured":"Bulgar A, Weeks L, Miao Y, Yang S, Xu Y, Guo C, et al. Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair. Cell Death Dis. 2012;3:e252.","journal-title":"Cell Death Dis"},{"key":"1864_CR115","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/1535-7163.MCT-13-0172","volume":"12","author":"LD Weeks","year":"2013","unstructured":"Weeks LD, Fu P, Gerson SL. Uracil\u2013DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed. Mol Cancer Ther. 2013;12:2248\u201360.","journal-title":"Mol Cancer Ther"},{"key":"1864_CR116","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/1535-7163.MCT-11-0781","volume":"11","author":"PM Wilson","year":"2012","unstructured":"Wilson PM, LaBonte MJ, Lenz H-J, Mack PC, Ladner RD. Inhibition of dUTPase induces synthetic lethality with thymidylate synthase\u2013targeted therapies in non\u2013small cell lung cancer. Mol Cancer Ther. 2012;11:616\u201328.","journal-title":"Mol Cancer Ther"},{"key":"1864_CR117","doi-asserted-by":"publisher","first-page":"8935","DOI":"10.1074\/jbc.M209578200","volume":"278","author":"L Rothem","year":"2003","unstructured":"Rothem L, Aronheim A, Assaraf YG. Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells. J Biol Chem. 2003;278:8935\u201341.","journal-title":"J Biol Chem"},{"key":"1864_CR118","doi-asserted-by":"publisher","first-page":"8735","DOI":"10.1158\/1078-0432.CCR-04-0932","volume":"10","author":"R Zhao","year":"2004","unstructured":"Zhao R, Chattopadhyay S, Hanscom M, Goldman ID. Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier. Clin Cancer Res. 2004;10:8735\u201342.","journal-title":"Clin Cancer Res"},{"key":"1864_CR119","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1158\/0008-5472.CAN-03-3953","volume":"64","author":"R Zhao","year":"2004","unstructured":"Zhao R, Hanscom M, Chattopadhyay S, Goldman ID. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway. Cancer Res. 2004;64:3313\u20139.","journal-title":"Cancer Res"},{"key":"1864_CR120","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ijc.10829","volume":"103","author":"E Liani","year":"2003","unstructured":"Liani E, Rothem L, Bunni MA, Smith CA, Jansen G, Assaraf YG. Loss of folylpoly-\u03b3-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003;103:587\u201399.","journal-title":"Int J Cancer"},{"key":"1864_CR121","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/00001813-199906000-00010","volume":"10","author":"S Cheradame","year":"1999","unstructured":"Cheradame S, Chazal M, Fischel J, Formento P, Renee N, Milano G. Variable intrinsic sensitivity of human tumor cell lines to raltitrexed (Tomudex) and folylpolyglutamate synthetase activity. Anticancer Drugs. 1999;10:505\u201310.","journal-title":"Anticancer Drugs"},{"key":"1864_CR122","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/0006-2952(96)00057-3","volume":"51","author":"JC Drake","year":"1996","unstructured":"Drake JC, Allegra CJ, Moran RG, Johnston PG. Resistance to tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines. Biochem Pharmacol. 1996;51:1349\u201355.","journal-title":"Biochem Pharmacol"},{"key":"1864_CR123","first-page":"4362","volume":"113","author":"M Stark","year":"2009","unstructured":"Stark M, Wichman C, Avivi I, Assaraf YG. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Am J Hematol. 2009;113:4362\u20139.","journal-title":"Am J Hematol"},{"key":"1864_CR124","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0006-2952(01)00824-3","volume":"63","author":"R Mauritz","year":"2002","unstructured":"Mauritz R, Peters GJ, Priest DG, Assaraf YG, Drori S, Kathmann I, et al. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol. 2002;63:105\u201315.","journal-title":"Biochem Pharmacol"},{"key":"1864_CR125","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.drup.2006.09.001","volume":"9","author":"YG Assaraf","year":"2006","unstructured":"Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updates. 2006;9:227\u201346.","journal-title":"Drug Resist Updates"},{"key":"1864_CR126","doi-asserted-by":"publisher","first-page":"8414","DOI":"10.1158\/0008-5472.CAN-04-4547","volume":"65","author":"A Shafran","year":"2005","unstructured":"Shafran A, Ifergan I, Bram E, Jansen G, Kathmann I, Peters GJ, et al. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res. 2005;65:8414\u201322.","journal-title":"Cancer Res"},{"key":"1864_CR127","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1111\/j.1349-7006.2010.01690.x","volume":"101","author":"T Uemura","year":"2010","unstructured":"Uemura T, Oguri T, Ozasa H, Takakuwa O, Miyazaki M, Maeno K, et al. ABCC11\/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci. 2010;101:2404\u201310.","journal-title":"Cancer Sci"},{"key":"1864_CR128","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.3390\/molecules26071856","volume":"26","author":"Y-H Kang","year":"2021","unstructured":"Kang Y-H, Lee J-S, Lee N-H, Kim S-H, Seo C-S, Son C-G. Coptidis rhizoma extract reverses 5-fluorouracil resistance in HCT116 human colorectal cancer cells via modulation of thymidylate synthase. Molecules. 2021;26:1856.","journal-title":"Molecules"},{"key":"1864_CR129","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1158\/1535-7163.MCT-06-0419","volume":"5","author":"J-H Lee","year":"2006","unstructured":"Lee J-H, Park J-H, Jung Y, Kim J-H, Jong H-S, Kim T-Y, et al. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther. 2006;5:3085\u201395.","journal-title":"Mol Cancer Ther"},{"key":"1864_CR130","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.drup.2011.08.001","volume":"14","author":"F Crea","year":"2011","unstructured":"Crea F, Nobili S, Paolicchi E, Perrone G, Napoli C, Landini I, et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Updates. 2011;14:280\u201396.","journal-title":"Drug Resist Updates"},{"key":"1864_CR131","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/j.1349-7006.2010.01559.x","volume":"101","author":"R Noro","year":"2010","unstructured":"Noro R, Miyanaga A, Minegishi Y, Okano T, Seike M, Soeno C, et al. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU\/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21waf1\/cip1 expression. Cancer Sci. 2010;101:1424\u201330.","journal-title":"Cancer Sci"},{"key":"1864_CR132","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/ijc.24403","volume":"125","author":"W Fazzone","year":"2009","unstructured":"Fazzone W, Wilson PM, LaBonte MJ, Lenz HJ, Ladner RD. Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. Int J Cancer. 2009;125:463\u201373.","journal-title":"Int J Cancer"},{"key":"1864_CR133","doi-asserted-by":"publisher","first-page":"782","DOI":"10.4161\/cbt.8.9.8118","volume":"8","author":"E Di Gennaro","year":"2009","unstructured":"Di Gennaro E, Bruzzese F, Pepe S, Leone A, Delrio P, Subbarayan P, et al. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol Ther. 2009;8:782\u201391.","journal-title":"Cancer Biol Ther"},{"key":"1864_CR134","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1158\/1541-7786.MCR-17-0215","volume":"16","author":"Y Yan","year":"2018","unstructured":"Yan Y, Qing Y, Pink JJ, Gerson SL. Loss of uracil DNA glycosylase selectively resensitizes p53-mutant and-deficient cells to 5-FdU. Mol Cancer Res. 2018;16:212\u201321.","journal-title":"Mol Cancer Res"},{"key":"1864_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-020-02318-8","volume":"18","author":"TS Iveland","year":"2020","unstructured":"Iveland TS, Hagen L, Sharma A, Sousa MM, Sarno A, Wollen KL, et al. HDACi mediate UNG2 depletion, dysregulated genomic uracil and altered expression of oncoproteins and tumor suppressors in B-and T-cell lines. J Transl Med. 2020;18:1\u201321.","journal-title":"J Transl Med"},{"key":"1864_CR136","doi-asserted-by":"publisher","first-page":"175883592092958","DOI":"10.1177\/1758835920929589","volume":"12","author":"A Avallone","year":"2020","unstructured":"Avallone A, Piccirillo MC, Di Gennaro E, Romano C, Calabrese F, Roca MS, et al. Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin\/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol. Ther Adv Med Oncol. 2020;12:1758835920929589.","journal-title":"Ther Adv Med Oncol."},{"key":"1864_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-875","volume":"14","author":"A Avallone","year":"2014","unstructured":"Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, et al. Phase 1\/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid-short RadioTherapy-rectum 3rd trial). BMC Cancer. 2014;14:1\u201312.","journal-title":"BMC Cancer"},{"key":"1864_CR138","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00280-011-1762-1","volume":"69","author":"M Fakih","year":"2012","unstructured":"Fakih M, Groman A, McMahon J, Wilding G, Muindi J. A randomized phase II study of two doses of vorinostat in combination with 5-FU\/LV in patients with refractory colorectal cancer. Cancer Chemother Pharmacol. 2012;69:743\u201351.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1864_CR139","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00280-009-1236-x","volume":"65","author":"PM Wilson","year":"2010","unstructured":"Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, et al. A phase I\/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol. 2010;65:979\u201388.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1864_CR140","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-08-2999","volume":"15","author":"MG Fakih","year":"2009","unstructured":"Fakih MG, Pendyala L, Fetterly G, Toth K, Zwiebel JA, Espinoza-Delgado I, et al. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res. 2009;15:3189\u201395.","journal-title":"Clin Cancer Res"},{"key":"1864_CR141","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.canlet.2010.07.020","volume":"299","author":"K-H Lee","year":"2010","unstructured":"Lee K-H, Hur H-S, Im S-A, Lee J, Kim H-P, Yoon Y-K, et al. RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. Cancer Lett. 2010;299:22\u20138.","journal-title":"Cancer Lett"},{"key":"1864_CR142","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.18632\/oncotarget.1760","volume":"5","author":"S Kawabata","year":"2014","unstructured":"Kawabata S, Chiang C-T, Tsurutani J, Shiga H, Arwood ML, Komiya T, et al. Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer. Oncotarget. 2014;5:1062.","journal-title":"Oncotarget"},{"key":"1864_CR143","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1097\/JTO.0b013e3182307ede","volume":"6","author":"J Vansteenkiste","year":"2011","unstructured":"Vansteenkiste J, Solomon B, Boyer M, Wolf J, Miller N, Di Scala L, et al. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model. J Thorac Oncol. 2011;6:2120\u20139.","journal-title":"J Thorac Oncol"},{"key":"1864_CR144","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s10120-013-0249-7","volume":"17","author":"A Nakamura","year":"2014","unstructured":"Nakamura A, Nakajima G, Okuyama R, Kuramochi H, Kondoh Y, Kanemura T, et al. Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in 5-fluorouracil-resistant gastric cancer cells with upregulated expression of thymidylate synthase. Gastric Cancer. 2014;17:188\u201395.","journal-title":"Gastric Cancer"},{"key":"1864_CR145","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/sj.bjp.0704394","volume":"134","author":"PJ Ferguson","year":"2001","unstructured":"Ferguson PJ, DeMoor JM, Vincent MD, Koropatnick J. Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells. Br J Pharmacol. 2001;134:1437\u201346.","journal-title":"Br J Pharmacol"},{"key":"1864_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2021.7978","volume":"45","author":"T Suetsugu","year":"2021","unstructured":"Suetsugu T, Mori R, Futamura M, Fukada M, Tanaka H, Yasufuku I, et al. Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines. Oncol Rep. 2021;45:1\u20138.","journal-title":"Oncol Rep"},{"key":"1864_CR147","first-page":"2538","volume":"6","author":"SJ Welsh","year":"2000","unstructured":"Welsh SJ, Titley J, Brunton L, Valenti M, Monaghan P, Jackman AL, et al. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues. Clin Cancer Res. 2000;6:2538\u201346.","journal-title":"Clin Cancer Res"},{"key":"1864_CR148","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3892\/or.2010.835","volume":"24","author":"M Fukushima","year":"2010","unstructured":"Fukushima M, Sakamoto K, Ohshimo H, Nakagawa F, Taguchi T. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase. Oncol Rep. 2010;24:835\u201342.","journal-title":"Oncol Rep"},{"key":"1864_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.718675","author":"Y Sato","year":"2021","unstructured":"Sato Y, Tomita M, Soga T, Ochiai A, Makinoshima H. Upregulation of thymidylate synthase induces pemetrexed resistance in malignant pleural mesothelioma. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.718675.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1864_CR150","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.1021\/acsomega.1c06394","volume":"7","author":"C Kurasaka","year":"2022","unstructured":"Kurasaka C, Nishizawa N, Ogino Y, Sato A. Trapping of 5-fluorodeoxyuridine monophosphate by thymidylate synthase confers resistance to 5-fluorouracil. ACS Omega. 2022;7(7):6046\u201352.","journal-title":"ACS Omega"},{"key":"1864_CR151","doi-asserted-by":"publisher","first-page":"e63338","DOI":"10.1371\/journal.pone.0063338","volume":"8","author":"A Buqu\u00e9","year":"2013","unstructured":"Buqu\u00e9 A, Aresti U, Calvo B, Jangi Sh, Muhialdin AM, Carrera S, Azkona E, Rubio I, L\u00f3pez-Vivanco G. Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells. PLoS ONE. 2013;8:e63338.","journal-title":"PLoS ONE"},{"key":"1864_CR152","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1158\/1535-7163.MCT-17-0911","volume":"17","author":"W Yano","year":"2018","unstructured":"Yano W, Yokogawa T, Wakasa T, Yamamura K, Fujioka A, Yoshisue K, et al. TAS-114, a first-in-class dual dUTPase\/DPD inhibitor, demonstrates potential to improve therapeutic efficacy of fluoropyrimidine-based chemotherapy. Mol Cancer Ther. 2018;17:1683\u201393.","journal-title":"Mol Cancer Ther"},{"key":"1864_CR153","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/cas.14718","volume":"112","author":"T Yokogawa","year":"2021","unstructured":"Yokogawa T, Yano W, Tsukioka S, Osada A, Wakasa T, Ueno H, et al. dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA-repair-defective human cancer cells. Cancer Sci. 2021;112:422\u201332.","journal-title":"Cancer Sci"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01864-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-022-01864-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01864-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T22:30:33Z","timestamp":1673821833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-022-01864-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":153,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["1864"],"URL":"https:\/\/doi.org\/10.1007\/s12032-022-01864-z","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,29]]},"assertion":[{"value":"7 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable (Since, it is a review article).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consented to the publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"3"}}